See more : ACI Worldwide, Inc. (ACIW) Income Statement Analysis – Financial Results
Complete financial analysis of Insmed Incorporated (INSM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Insmed Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Urgent.ly Inc. Common Stock (ULY) Income Statement Analysis – Financial Results
- Waskahigan Oil & Gas Corp. (WOGC.CN) Income Statement Analysis – Financial Results
- Mazda Motor Corporation (MZDAF) Income Statement Analysis – Financial Results
- Jupiter Life Line Hospitals Limited (JLHL.NS) Income Statement Analysis – Financial Results
- MIRAIT ONE Corporation (1417.T) Income Statement Analysis – Financial Results
Insmed Incorporated (INSM)
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.21M | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M | 0.00 | 0.00 | 0.00 | 11.50M | 11.50M | 0.00 | 4.42M | 6.92M | 10.37M | 11.70M | 7.53M | 991.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 663.16K |
| Cost of Revenue | 65.57M | 55.13M | 44.15M | 39.87M | 24.21M | 2.42M | 2.90M | 2.44M | 1.98M | 33.53M | 29.64M | 21.37M | 0.00 | 0.00 | 0.00 | 0.00 | 576.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.57K |
| Gross Profit | 239.64M | 190.23M | 144.31M | 124.54M | 112.26M | 7.41M | -2.90M | -2.44M | -1.98M | -22.03M | -18.14M | -21.37M | 4.42M | 6.92M | 10.37M | 11.70M | 6.95M | -499.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 749.74K |
| Gross Profit Ratio | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | 0.00% | 0.00% | 0.00% | -191.61% | -157.77% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 92.35% | -50.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 113.05% |
| Research & Development | 571.01M | 397.52M | 272.74M | 181.16M | 131.71M | 145.28M | 109.75M | 122.72M | 74.28M | 56.29M | 44.28M | 29.78M | 27.92M | 4.76M | 9.21M | 21.05M | 18.94M | 21.09M | 21.84M | 23.32M | 7.14M | 18.08M | 35.51M | 21.61M | 6.35M |
| General & Administrative | 344.50M | 244.98M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 0.00 | 0.00 | 0.00 | 0.00 | 5.73M | 2.98M | 3.48M | 2.98M | 4.98M | 9.55M | 0.00 |
| Selling & Marketing | 0.00 | 20.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 344.50M | 265.78M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 25.68M | 5.73M | 4.24M | 3.48M | 2.98M | 4.98M | 9.55M | 2.44M |
| Other Expenses | 33.75M | 5.05M | 5.05M | 5.00M | 4.99M | 602.00K | 300.00K | 119.00K | -33.00K | 141.00K | -33.00K | 0.00 | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 32.79M | 5.73M | 4.24M | 3.60M | 18.37M | 95.00K | 0.00 | 2.53M |
| Operating Expenses | 949.26M | 668.36M | 512.07M | 389.77M | 347.50M | 314.75M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.39M | 53.87M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.88M |
| Cost & Expenses | 1.01B | 723.48M | 556.22M | 429.65M | 371.71M | 317.17M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.97M | 55.36M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.79M |
| Interest Income | 0.00 | 11.08M | 174.00K | 1.70M | 9.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.85M | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 607.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.69M | 26.45M | 40.47M | 29.56M | 27.71M | 25.47M | 5.93M | 3.50M | 2.89M | 2.42M | 2.41M | 763.00K | 10.00K | 109.00K | 781.00K | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.58M | 24.27M | 27.85M | 20.08M | 10.18M | 4.83M | 2.90M | 2.44M | 1.98M | 1.07M | 680.00K | 561.00K | 343.00K | 54.00K | 707.00K | 1.04M | 406.00K | 3.37M | 12.90M | 34.00K | 96.00K | 346.00K | 1.54M | 789.00K | 86.57K |
| EBITDA | -660.18M | -429.44M | -375.09M | -250.37M | -215.67M | -293.78M | -184.10M | -170.24M | -115.28M | -86.09M | -54.20M | -40.05M | -59.31M | -6.19M | 120.32M | -13.37M | -18.87M | -49.07M | -13.79M | -27.17M | -10.49M | -34.15M | -38.64M | -30.31M | -8.04M |
| EBITDA Ratio | -216.30% | -186.75% | -198.12% | -158.03% | -169.11% | -3,106.12% | 0.00% | 0.00% | 0.00% | -758.47% | -472.77% | 0.00% | -801.13% | -116.14% | -76.81% | -109.99% | -266.08% | -4,429.97% | -11,096.95% | -19,993.43% | -6,914.00% | -830.03% | -13,055.41% | 33,536.67% | -1,212.93% |
| Operating Income | -709.63M | -478.12M | -367.76M | -265.23M | -235.25M | -307.34M | -188.92M | -173.40M | -117.49M | -87.37M | -55.02M | -42.44M | -61.72M | -8.09M | -8.67M | -14.41M | -20.44M | -54.37M | -27.43M | -27.43M | -10.59M | -37.02M | -40.19M | -81.54M | -8.13M |
| Operating Income Ratio | -232.51% | -194.87% | -195.14% | -161.32% | -172.38% | -3,124.94% | 0.00% | 0.00% | 0.00% | -759.70% | -478.39% | 0.00% | -1,397.31% | -116.92% | -83.62% | -123.18% | -271.47% | -5,486.68% | -20,941.98% | -20,018.25% | -7,057.33% | -1,893.81% | -13,576.35% | -135,891.67% | -1,225.98% |
| Total Other Income/Expenses | -37.39M | -2.03M | -61.32M | -27.46M | -18.32M | -16.74M | -4.00M | -2.78M | -2.66M | -2.22M | -2.28M | -1.14M | -23.94M | 1.74M | 127.50M | -1.26M | 477.00K | -1.77M | -13.50M | 222.00K | 288.00K | 607.00K | 3.02M | 1.87M | 0.00 |
| Income Before Tax | -747.01M | -480.15M | -436.41M | -292.69M | -253.56M | -324.08M | -192.92M | -176.18M | -120.15M | -89.58M | -57.29M | -41.37M | -59.66M | -6.36M | 118.83M | -15.67M | -19.96M | -56.14M | -40.93M | -36.42M | -10.30M | -36.42M | -37.17M | -79.66M | 0.00 |
| Income Before Tax Ratio | -244.76% | -195.69% | -231.57% | -178.02% | -185.80% | -3,295.13% | 0.00% | 0.00% | 0.00% | -778.97% | -498.21% | 0.00% | -1,350.78% | -91.84% | 1,145.54% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -26,581.75% | -6,865.33% | -1,862.76% | -12,557.09% | -132,770.00% | 0.00% |
| Income Tax Expense | 2.56M | 1.38M | -1.76M | 1.40M | 777.00K | 201.00K | -272.00K | 98.00K | -1.97M | -10.42M | -1.22M | 763.00K | 9.18M | 78.00K | 477.00K | 1.26M | 0.00 | 1.77M | 0.00 | -9.21M | -288.00K | 1.93M | -74.34M | 200.00K | -337.57K |
| Net Income | -749.57M | -481.53M | -434.65M | -294.09M | -254.34M | -324.28M | -192.65M | -176.27M | -118.18M | -79.16M | -56.07M | -41.37M | -59.66M | -6.43M | 118.35M | -15.67M | -19.96M | -56.14M | -40.93M | -27.20M | -10.30M | -36.42M | -37.17M | -79.86M | -7.79M |
| Net Income Ratio | -245.59% | -196.26% | -230.63% | -178.87% | -186.37% | -3,297.17% | 0.00% | 0.00% | 0.00% | -688.34% | -487.59% | 0.00% | -1,350.78% | -92.96% | 1,140.94% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -19,856.20% | -6,865.33% | -1,862.76% | -12,557.09% | -133,103.33% | -1,175.08% |
| EPS | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| EPS Diluted | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| Weighted Avg Shares Out | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.84M | 66.58M | 61.85M | 58.51M | 43.02M | 34.98M | 26.52M | 23.35M | 13.25M | 12.71M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
| Weighted Avg Shares Out (Dil) | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.89M | 66.58M | 61.89M | 58.63M | 43.10M | 34.98M | 26.55M | 23.35M | 13.25M | 12.73M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024...
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
—Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J. , Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of...
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J. , Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to...
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
BRIDGEWATER, N.J. , Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its...
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J. , Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Oct. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards...
These 12 Stocks are Ripe for a Short Squeeze
Subscribers to Chart of the Week received this commentary on Sunday, September 8.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Sept. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards...
Source: https://incomestatements.info
Category: Stock Reports